KROS Key Statistics, Chart & Performance
The current stock price of KROS is 17.48 USD. In the past month the price increased by 16.3%. In the past year, price decreased by -69.73%.
KROS Latest News, Press Relases and Analysis
KROS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.25B | ||
| AMGN | AMGEN INC | 15.8 | 185.98B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.15B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.78B | ||
| BIIB | BIOGEN INC | 10.88 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 21.98B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About KROS
Company Profile
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 148 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Company Info
KEROS THERAPEUTICS INC
1050 Waltham Street, Suite 302
Lexington MASSACHUSETTS 02421 US
CEO: Jasbir Seehra
Employees: 148
Phone: 16173146297
KEROS THERAPEUTICS INC / KROS FAQ
What does KEROS THERAPEUTICS INC do?
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 148 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Can you provide the latest stock price for KEROS THERAPEUTICS INC?
The current stock price of KROS is 17.48 USD. The price decreased by -0.11% in the last trading session.
Does KROS stock pay dividends?
KROS does not pay a dividend.
What is the ChartMill rating of KEROS THERAPEUTICS INC stock?
KROS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is KROS stock listed?
KROS stock is listed on the Nasdaq exchange.
What is the next earnings date for KROS stock?
KEROS THERAPEUTICS INC (KROS) will report earnings on 2026-02-24, after the market close.
Can you provide the short interest for KROS stock?
The outstanding short interest for KEROS THERAPEUTICS INC (KROS) is 15.24% of its float.
KROS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to KROS. When comparing the yearly performance of all stocks, KROS is a bad performer in the overall market: 88.26% of all stocks are doing better.
KROS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to KROS. KROS has an excellent financial health rating, but there are some minor concerns on its profitability.
KROS Financial Highlights
Over the last trailing twelve months KROS reported a non-GAAP Earnings per Share(EPS) of 1.54. The EPS increased by 129.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 26.12% | ||
| ROA | 8.68% | ||
| ROE | 9.16% | ||
| Debt/Equity | 0 |
KROS Forecast & Estimates
17 analysts have analysed KROS and the average price target is 23.72 USD. This implies a price increase of 35.67% is expected in the next year compared to the current price of 17.48.
For the next year, analysts expect an EPS growth of 118.16% and a revenue growth 39294.7% for KROS